GPRC5D Directed CAR T-Cell Therapy | University of Alabama | Susan Bal, MD | ASH 2023

Canakinumab & Darbepoetin Alfa in Lower-Risk MDS | David Sallman, MD | ASH 2023

Teclistamab: Outpatient Step-up Dosing and Real-World Outcomes | Tyler Sandahl, PharmD | ASH 2023

Insurance Impact on Outcomes for Rural Hematologic Patients | Kingsley Nnawuba, MD | ASH 2023

Drug study for Older Patients with Advanced Stage Hodgkin Lymphoma

Real-World Safety and Efficacy of Teclistamab | Hamza Hashmi | ASH 2023

Efficacy of Reduced Dosing of Talquetamab in Relapsed Refractory Myeloma | Ajai Chari, MD | ASH 2023

Evaluating IWG Response Criteria for MDS Patients | Jan Bewersdorf, MD | ASH 2023

Myeloma Treatment Comparison: RVd vs. D-RVd Outcomes | Nisha Joseph, MD | ASH 2023

ABBV-525 in CLL and Non-Hodgkin Lymphoma Patients | Meghan Thompson, MD | ASH 2023

ABBV-525 in CLL and Non-Hodgkin Lymphoma Patients

Predictors of CRS and Neurotoxicity in Lymphoma Patients

IDH2 Mutation Allows Myeloid Differentiation | Jane Liesveld, MD | ASH 2023

Updated Safety and Efficacy Results of ABBV-383 | Ravi Vij, MD, MBA | ASH 2023

MGUS and Thrombotic Events: iStopMM Study Results | Sæmundur Rögnvaldsson, MD, PhD | ASH 2023